Thermo Fisher Scientific (TMO)
Supplies laboratory tools, diagnostics, and outsourced drug-development and manufacturing services.
Something off on this page? Send us feedback.
Supplies life-science tools, analytical instruments, diagnostics, laboratory products, and outsourced clinical-development and drug-manufacturing services worldwide. A broad portfolio of proprietary products, third-party distribution, and regulated services ties demand to pharmaceutical and biotech research, laboratory capital spending, and government funding.
Supplies research, clinical, and industrial laboratories with instruments, reagents, consumables, diagnostics, software, and outsourced drug-development services through a global direct-sales and distribution network.
Life Sciences Solutions covers biosciences, genetic analysis, and bioproduction; Analytical Instruments spans chromatography, mass spectrometry, chemical analysis, and electron microscopy. Specialty Diagnostics provides clinical and immunodiagnostic products, while Laboratory Products and Biopharma Services combines Fisher Scientific distribution with Patheon manufacturing, PPD clinical research, and Clario trial-endpoint data.
The broad portfolio serves pharmaceutical and biotech, healthcare, academic, government, semiconductor, environmental, and industrial markets, with roughly half of revenue generated outside the United States. Demand depends on customer research and capital budgets and government funding, while diagnostics, clinical research, and drug manufacturing operate under extensive quality and regulatory requirements.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Piper Sandler | Initiate | Rating: — | |
| Sep 9, 2026 | Scotiabank | Initiate | Rating: — | |
| Sep 9, 2026 | Citigroup | Downgrade | ||
| Sep 9, 2026 | Wells Fargo | Downgrade | ||
| Sep 9, 2026 | BMO Capital | Downgrade | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $4.06B · Total debt $42.55B · Total assets $113.17B · Shareholders' equity $52.68B
- Revenue
- $11.99B
- Operating income
- $2.09B
- Net income
- $1.74B
HistoryDividendAnnual yield
| Institutions | 91.69% | 339.01M shares | |
|---|---|---|---|
| 2,703 holders · as of Jun 30, 2026 | |||
| Insiders | 0.13% | 466.2K shares | |
| 22 holders · as of Sep 1, 2026 | |||
| Other | 8.18% | 30.27M shares | |
| remainder | |||
369.75M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.36% | 30.92M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.57% | 24.28M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.55% | 16.83M | as of Jun 30, 2026 |
FMR LLCInstitution | 3.81% | 14.08M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 2.91% | 10.76M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Gianluca Pettiti | officer: President & COO | −3,733 | $614.38 |
| Aug 24, 2026 | Marc N. Casper | director, officer: Chairman & CEO | −275 | $627.05 |
| Aug 21, 2026 | Marc N. Casper | director, officer: Chairman & CEO | −10,000 | $626.92 |
| Aug 20, 2026 | Marc N. Casper | director, officer: Chairman & CEO | −10,000 | $629.27 |
| Aug 19, 2026 | Lisa P. Britt | officer: Sr. VP and Chief HR Officer | −11,440 | $613.12 |
- Danaher
Broadest portfolio peer across bioprocessing, diagnostics, and instruments.
- IQVIA
World's largest CRO — head-to-head with TMO's PPD clinical research unit.
- Agilent Technologies
Primary analytical instruments rival in chromatography, mass spec, and services.
- Waters
LC and LC-MS specialist competing in the Analytical Instruments segment.
- QIAGEN
Molecular diagnostics specialist in sample prep, PCR, and NGS.
- Illumina
NGS market leader — contests Ion Torrent and Applied Biosystems sequencing.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | $658.82 | +0.01% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $218.36 | +1.17% | $151.67B | 38.3 | 24.7 | 6.0 | +5.5% |
| IQVIA | $269.47 | −0.15% | $44.42B | 33.5 | 19.8 | 2.6 | +8.7% |
| Agilent Technologies | $164.69 | +1.70% | $45.75B | 31.9 | 25.1 | 6.2 | +8.1% |
| Waters | $428.72 | +1.13% | $41.62B | 105.7 | 27.4 | 9.0 | +113.3% |
| QIAGEN | $44.01 | −1.72% | $9.24B | 23.0 | 17.6 | 4.4 | +0.3% |
| Illumina | $243.77 | +2.07% | $36.13B | 44.6 | 42.7 | 8.0 | +9.4% |
| Median | 35.9 | 24.9 | 6.1 | +8.4% |